Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Segment Financial Information

Segment financial information used by the CODM to assess segment performance and make decisions about resource allocation was as follows (in thousands):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Research and development:
External expenses
ELVN-001	$	4,684		$	3,164		$	15,662		$	11,763
ELVN-002		2,337			8,414			13,977			22,434
Other (1)		2,645			2,933			9,232			7,252
Internal expenses
Salaries and benefits		4,202			3,534			12,724			9,453
Stock-based compensation		3,706			2,598			10,987			7,355
Facilities, laboratory supplies and other (2)		651			615			2,029			1,797
Total research and development expenses		18,225			21,258			64,611			60,054
General and administrative:
Salaries and benefits		1,354			1,276			4,104			3,647
Stock-based compensation		3,479			2,578			10,721			7,480
Other (3)		2,038			1,956			5,937			6,477
Total general and administrative expenses		6,871			5,810			20,762			17,604
Total operating expenses		25,096			27,068			85,373			77,658
Other income (expense), net		4,948			3,912			11,346			11,814
Net loss	$	(20,148	)	$	(23,156	)	$	(74,027	)	$	(65,844	)

(1) Other external research and development costs primarily represent contract research, preclinical studies and manufacturing costs that are not related to ELVN-001 and ELVN-002, as well as general consulting costs.

(2) Other internal research and development costs primarily represent travel, expensed software and depreciation.

(3) Other general and administrative costs primarily represent insurance, professional fees, expensed software, taxes and travel.

Enliven Therapeutics, Inc. 10-Q